BenzingaT3·7mo ago
VYNE VYNE Therapeutics Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VYNE
—
—
Key stats
Fair Value
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.71% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.71% |
| WACC | 9.63% |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -72.9% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -10523.5% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $34.07 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $35.53 |
| Bollinger Width / SMA20 | 165.0% (drives anchor stability) |
| Net Debt | $-0.0B |
Peers used for multiples: ABT, PFE, REGN
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
—
Deviation
—
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | $1.84 | 0% | |
| Peer P/E | n/a | 0% | median 18.7× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 16.5× · 3 peers |
| Peer P/B | n/a | 0% | median 2.2× · 3 peers |
| Peer P/S | n/a | 0% | median 4.0× · 3 peers |
| Market Anchor (SMA50) | $34.07 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-07-28 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 10
- List Date
- 2018-01-25
- CIK
- 0001566044
- Last Earnings
- Jul 28
- Headquarters
- Bridgewater, NJ
- Homepage
- https://www.vynetherapeutics.com
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
Insufficient price history — listed 3210 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $35.53
SMA 50: $34.07
SMA 200: $28.15
Current: $28.56
EMA 12: $36.11
EMA 26: $35.39
MACD: 0.7217 | Signal: -0.6762
BULLISH
ADX (14): 32.17
TREND
+DI: 18.38
−DI: 34.94
Momentum Oscillators
RSI (14): 39.73
NEUTRAL
Stoch %K: 41.85
Stoch %D: 68.21
Williams %R: -77.99
Volume & Volatility
BB Upper: $45.95
BB Lower: $25.11
NEUTRAL
OBV: 4,846,886
Vol SMA 20: 44,267
Vol ROC: 58.02%
ATR: $4.10
True Range: $5.19
HV 20: 230.3%
HV 30: 187.2%
HV 60: 132.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-07-29T00:00:00 – 2026-07-27T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All VYNE news →
GlobeNewswire Inc.T3·10mo ago
GlobeNewswire Inc.T3·10mo ago
GlobeNewswire Inc.T3·15mo ago
GlobeNewswire Inc.T3·28mo ago
BenzingaT3·29mo ago
GlobeNewswire Inc.T3·29mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·32mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
3 of 3 under expected move
Avg Expected Move
62.31%
Avg Actual Move
10.35%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-05-06 | After-Close | 2.34% | 1.97% | 0.84x | Within |
| 2021-08-12 | unknown | 15.21% | 10.55% | 0.69x | Within |
| 2023-05-11 | unknown | 169.39% | 18.52% | 0.11x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
VYNE Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: —
7-DTE Move: —
Days to Exp: — (Unknown)
Options Flow · One expiry
Call Volume: —
Put Volume: —
P/C Volume: —
Call OI: —
Put OI: —
P/C OI: —
Total OI: —
ATM Options Pricing
ATM Call: —
ATM Put: —
Call %: —
Put %: —
Chain Summary
Chain Volume: 0
Chain OI: 0
Last Updated: 7/20/2023
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Jan 10 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Jan 10 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Insufficient price history — listed 3210 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.
VYNE Institutional Ownership (13F)
Filings for 2026-06-30
? 13F Guide
Diluted shares outstanding: 42,742,000 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
VYNE Insider Trading (Form 4)
Latest: 2026-07-24Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-24 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | Tax (F) | −15,405 | $0.90 | -$13.8K | EDGAR |
| 2026-07-24 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Tax (F) | −22,516 | $0.90 | -$20.2K | EDGAR |
| 2026-07-24 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | Tax (F) | −22,516 | $0.90 | -$20.2K | EDGAR |
| 2026-07-24 | David Domzalski | PRESIDENT AND CEO | Tax (F) | −79,391 | $0.90 | -$71.3K | EDGAR |
| 2026-07-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | Tax (F) | −2,370 | $0.65 | -$1.5K | EDGAR |
| 2026-07-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Tax (F) | −3,464 | $0.65 | -$2.3K | EDGAR |
| 2026-07-02 | David Domzalski | PRESIDENT AND CEO | Tax (F) | −12,214 | $0.65 | -$7.9K | EDGAR |
| 2026-07-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | Tax (F) | −3,464 | $0.65 | -$2.3K | EDGAR |
| 2026-06-02 | David Domzalski | PRESIDENT AND CEO | Award (A) | +30,791 | $0.31 | $9.5K | EDGAR |
| 2026-04-02 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | Tax (F) | −4,007 | $0.60 | -$2.4K | EDGAR |
| 2026-04-02 | David Domzalski | PRESIDENT AND CEO | Tax (F) | −14,232 | $0.60 | -$8.5K | EDGAR |
| 2026-04-02 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Tax (F) | −4,007 | $0.60 | -$2.4K | EDGAR |
| 2026-04-02 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | Tax (F) | −2,876 | $0.60 | -$1.7K | EDGAR |
| 2026-01-05 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | Tax (F) | −2,448 | $0.58 | -$1.4K | EDGAR |
| 2026-01-05 | David Domzalski | PRESIDENT AND CEO | Tax (F) | −12,684 | $0.58 | -$7.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VYNE Insider Holdings
5 insiders · @ $28.56
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David Domzalski | PRESIDENT AND CEO | 6,943 | $198.3K | $103.6K | 42 | 2026-07-24 |
| 2 | Iain Stuart | CHIEF SCIENTIFIC OFFICER | 1,919 | $54.8K | $0 | 30 | 2026-07-24 |
| 3 | Mutya Harsch | CHIEF LEGAL OFFICER AND GC | 1,918 | $54.8K | $25.0K | 34 | 2026-07-24 |
| 4 | Tyler Zeronda | CHIEF FINANCIAL OFFICER | 1,498 | $42.8K | $0 | 28 | 2026-07-24 |
| 5 | Patrick G Lepore | Director | 1,029 | $29.4K | $399.9K | 15 | 2025-12-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VYNE Board & Officers
As of SEC filings through Oct 30, 2026Directors 15
- Steven L Basta · since Jan 24, 2018
- Elisabeth Sandoval Little · since Mar 19, 2019
- David Domzalski · since Mar 9, 2020
- Sharon Barbari · since Mar 9, 2020
- Patrick G Lepore · since Sep 10, 2020
- Mona Ashiya · since Jul 27, 2026
- OrbiMed Capital GP X LLC (entity) · since Jul 27, 2026
- OrbiMed Genesis GP LLC (entity) · since Jul 27, 2026
- Orbimed Advisors LLC (entity) · since Jul 27, 2026
- Peter B. Silverman · since Jul 27, 2026
- Rebecca Frey · since Jul 27, 2026
- Steven L. Hoerter · since Jul 27, 2026
- Sven Ante Lundberg · since Jul 27, 2026
- William Richard White · since Jul 27, 2026
- Tyler Zeronda · listed since Jul 2026
Officers 7
- Rebecca Frey · Chief Executive Officer · since Jul 27, 2026
- Tyler Zeronda · Chief Financial Officer · listed since Mar 2022
- Rachael Alford · Chief Operating Officer · since Jul 27, 2026
- Iain Stuart · Chief Scientific Officer · since Mar 9, 2020
- Mutya Harsch · Chief Legal Officer and GC · since Mar 9, 2020
- Lori Payton · Chief Development Officer · since Jul 27, 2026
- Steven Ryder · Chief Medical Officer · since Jul 27, 2026
10% owners 3
- Joseph Edelman · listed since Jul 2026
- Perceptive Advisors LLC (entity) · listed since Jul 2026
- Perceptive Life Sciences Master Fund Ltd (entity) · listed since Jul 2026
Changes in the last 10 years (86)
| Jul 30, 2026 | Roderick Wong reported in an SEC filing no longer being a 10% owner |
| Jul 30, 2026 | RTW Fund Group GP, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 29, 2026 | Tyler Zeronda first listed as a director in an SEC filing |
| Jul 29, 2026 | Perceptive Life Sciences Master Fund Ltd first listed as a 10% owner in an SEC filing |
| Jul 29, 2026 | Perceptive Advisors LLC first listed as a 10% owner in an SEC filing |
| Jul 29, 2026 | Joseph Edelman first listed as a 10% owner in an SEC filing |
| Jul 27, 2026 | William Richard White became a director |
| Jul 27, 2026 | Sven Ante Lundberg became a director |
| Jul 27, 2026 | Steven Ryder became Chief Medical Officer |
| Jul 27, 2026 | Steven L. Hoerter became a director |
| Jul 27, 2026 | Roderick Wong became a 10% owner |
| Jul 27, 2026 | Rebecca Frey became a director |
| Jul 27, 2026 | Rebecca Frey became Chief Executive Officer |
| Jul 27, 2026 | Rachael Alford became Chief Operating Officer |
| Jul 27, 2026 | RTW Fund Group GP, LLC became a 10% owner |
| Jul 27, 2026 | Peter B. Silverman became a director |
| Jul 27, 2026 | Orbimed Advisors LLC became a director |
| Jul 27, 2026 | OrbiMed Genesis GP LLC became a director |
| Jul 27, 2026 | OrbiMed Capital GP X LLC became a director |
| Jul 27, 2026 | Mona Ashiya became a director |
| Jul 27, 2026 | Lori Payton became Chief Development Officer |
| Aug 13, 2025 | The company announced the departure of Anthony D Bruno from the board in an SEC filing |
| Aug 11, 2025 | The company announced the departure of Christine Borowski from the board in an SEC filing |
| Dec 29, 2023 | Christine Borowski became a director |
| Nov 1, 2023 | Len Blavatnik became a 10% owner |
| Nov 1, 2023 | Access Industries Management, LLC became a 10% owner |
| Nov 1, 2023 | Access Industries Holdings LLC became a 10% owner |
| Nov 1, 2023 | AI Biotechnology LLC became a 10% owner |
| Mar 18, 2022 | Tyler Zeronda listed as Chief Financial Officer (previously Interim CFO) in SEC filings |
| Jan 12, 2022 | The company announced the departure of Rex Bright from the board in an SEC filing |
| Aug 18, 2021 | Perceptive Life Sciences Master Fund Ltd reported in an SEC filing no longer being a 10% owner |
| Aug 18, 2021 | Perceptive Advisors LLC reported in an SEC filing no longer being a 10% owner |
| Aug 18, 2021 | Joseph Edelman reported in an SEC filing no longer being a 10% owner |
| Jun 18, 2021 | Tyler Zeronda became Interim CFO |
| Feb 1, 2021 | Joseph Edelman no longer listed as a director in SEC filings |
| Sep 10, 2020 | Patrick G Lepore became a director |
| Mar 23, 2020 | Andrew Saik became Chief Financial Officer |
| Mar 11, 2020 | Steven L Basta no longer listed as Chief Executive Officer in SEC filings |
| Mar 9, 2020 | Stanley Hirsch became a director |
| Mar 9, 2020 | Sharon Barbari became a director |
| Mar 9, 2020 | Rex Bright became a director |
| Mar 9, 2020 | Perceptive Life Sciences Master Fund Ltd became a 10% owner |
| Mar 9, 2020 | Perceptive Advisors LLC became a 10% owner |
| Mar 9, 2020 | Mutya Harsch became Chief Legal Officer and GC |
| Mar 9, 2020 | Matthew T. Wiley became Chief Commercial Officer |
| Mar 9, 2020 | Joseph Edelman became a director |
| Mar 9, 2020 | Joseph Edelman became a 10% owner |
| Mar 9, 2020 | Ilan Hadar became CFO and Country Manager |
| Mar 9, 2020 | Iain Stuart became Chief Scientific Officer |
| Mar 9, 2020 | David Domzalski became a director |
| Mar 9, 2020 | David Domzalski became President and CEO |
| Mar 9, 2020 | Anthony D Bruno became a director |
| Aug 7, 2019 | Paul Kwon listed as Chief Scientific Officer (previously Chief Medical Officer) in SEC filings |
| Jun 17, 2019 | Ronald A. Krasnow became General Counsel and Chief Compliance Officer |
| Mar 19, 2019 | Elisabeth Sandoval Little became a director |
| Jul 26, 2018 | Presidio Partners 2007, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 26, 2018 | Presidio Partners 2007 GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 26, 2018 | Presidio Partners 2007 (Parallel), L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 26, 2018 | James F Watson reported in an SEC filing no longer being a 10% owner |
| Jul 26, 2018 | Faysal A. Sohail reported in an SEC filing no longer being a 10% owner |
| Jul 26, 2018 | David J Collier reported in an SEC filing no longer being a 10% owner |
| May 3, 2018 | Mary Spellman became Chief Medical Officer |
| Jan 29, 2018 | venBio Global Strategic Fund II L.P. reported in an SEC filing no longer being a 10% owner |
| Jan 24, 2018 | venBio Global Strategic Fund II L.P. became a 10% owner |
| Jan 24, 2018 | Vivo Capital VIII, LLC became a 10% owner |
| Jan 24, 2018 | Vivo Capital Surplus Fund VIII, L.P. became a 10% owner |
| Jan 24, 2018 | Vivo Capital Fund VIII, L.P. became a 10% owner |
| Jan 24, 2018 | Ted Ebel became a director |
| Jan 24, 2018 | Steven L Basta became a director |
| Jan 24, 2018 | Steven L Basta became Chief Executive Officer |
| Jan 24, 2018 | Scott M Whitcup became a director |
| Jan 24, 2018 | Remeditex Ventures LLC became a 10% owner |
| Jan 24, 2018 | Presidio Partners 2007, L.P. became a 10% owner |
| Jan 24, 2018 | Presidio Partners 2007 GP, L.P. became a 10% owner |
| Jan 24, 2018 | Presidio Partners 2007 (Parallel), L.P. became a 10% owner |
| Jan 24, 2018 | Paul L Berns became a director |
| Jan 24, 2018 | Paul Kwon became Chief Medical Officer |
| Jan 24, 2018 | Merck Sharp & Dohme Corp. became a 10% owner |
| Jan 24, 2018 | Merck & Co., Inc. became a 10% owner |
| Jan 24, 2018 | Kristine M Ball became Senior Vice President, Corporate Strategy and Chief Financial Officer |
| Jan 24, 2018 | James F Watson became a 10% owner |
| Jan 24, 2018 | Faysal A. Sohail became a 10% owner |
| Jan 24, 2018 | David W J McGirr became a director |
| Jan 24, 2018 | David J Collier became a 10% owner |
| Jan 24, 2018 | Albert Cha became a director |
| Jan 24, 2018 | Aaron Royston became a director |
Not reported recently (24)
- Access Industries Holdings LLC · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- Access Industries Management, LLC · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- AI Biotechnology LLC · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- Len Blavatnik · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- Matthew T. Wiley · Last reported as Chief Commercial Officer in an SEC filing dated Jul 2, 2021
- Andrew Saik · Last reported as Chief Financial Officer in an SEC filing dated Jun 2, 2021
- Stanley Hirsch · Last reported as a director in an SEC filing dated Apr 7, 2020
- Ilan Hadar · Last reported as CFO and Country Manager in an SEC filing dated Mar 11, 2020
- Kristine M Ball · Last reported as Senior Vice President, Corporate Strategy and Chief Financial Officer in an SEC filing dated Dec 16, 2019
- Paul Kwon · Last reported as Chief Scientific Officer in an SEC filing dated Dec 16, 2019
- Ronald A. Krasnow · Last reported as General Counsel and Chief Compliance Officer in an SEC filing dated Dec 13, 2019
- Scott M Whitcup · Last reported as a director in an SEC filing dated Aug 8, 2019
- Aaron Royston · Last reported as a director in an SEC filing dated Aug 8, 2019
- Paul L Berns · Last reported as a director in an SEC filing dated Aug 8, 2019
- David W J McGirr · Last reported as a director in an SEC filing dated Aug 8, 2019
- Ted Ebel · Last reported as a director in an SEC filing dated Aug 8, 2019
- Mary Spellman · Last reported as Chief Medical Officer in an SEC filing dated Dec 12, 2018
- Vivo Capital Fund VIII, L.P. · Last reported as a 10% owner in an SEC filing dated Jan 29, 2018
- Vivo Capital Surplus Fund VIII, L.P. · Last reported as a 10% owner in an SEC filing dated Jan 29, 2018
- Vivo Capital VIII, LLC · Last reported as a 10% owner in an SEC filing dated Jan 29, 2018
- Remeditex Ventures LLC · Last reported as a 10% owner in an SEC filing dated Jan 29, 2018
- Albert Cha · Last reported as a director in an SEC filing dated Jan 29, 2018
- Merck Sharp & Dohme Corp. · Last reported as a 10% owner in an SEC filing dated Jan 24, 2018
- Merck & Co., Inc. · Last reported as a 10% owner in an SEC filing dated Jan 24, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.41
TTM Revenue
$357.00K
TTM Net Income
$-17.95M
TTM Op. Cash Flow
—
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $86.00K | $-3.58M | $-0.08 | $-4.08M |
| Q4 '25 | 2025-12-31 | — | — | — | — |
| Q2 '25 | 2025-06-30 | $69.00K | $-5.75M | $-0.13 | $-10.80M |
| Q1 '25 | 2025-03-31 | $202.00K | $-8.61M | $-0.20 | $-11.46M |
| Q4 '24 | 2024-12-31 | $84.00K | $-12.02M | $-0.28 | $-9.00M |
| Q3 '24 | 2024-09-30 | $121.00K | $-12.16M | $-0.29 | $-8.51M |
| Q2 '24 | 2024-06-30 | $198.00K | $-9.41M | $-0.22 | $-8.48M |
| Q1 '24 | 2024-03-31 | $98.00K | $-6.25M | $-0.15 | $-7.98M |
| Q4 '23 | 2023-12-31 | $76.00K | $-6.19M | $4.04 | $-5.14M |
| Q3 '23 | 2023-09-30 | $114.00K | $-6.58M | $-2.01 | $-5.15M |
| Q2 '23 | 2023-06-30 | $135.00K | $-10.06M | $-3.09 | $-9.57M |
| Q1 '23 | 2023-03-31 | $99.00K | $-5.62M | $-1.74 | $-5.48M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-15
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-72.9%
ROA
-69.4%
Div Yield
0.00%
FCF Yield
—
Debt/Equity
0.00
Current Ratio
—
Market Cap
$0.00
as of 2026-07-28
VYNE vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 45.8 | +45.5% | +30.7% | 27 |
| JNJ Johnson & Johnson | $664.9B | 42.8 | +7.8% | +36.1% | 54 |
| ABBV ABBVIE INC. | $514.9B | 50.5 | +10.7% | +27.9% | 30 |
| MRK Merck & Co., Inc. | $361.7B | 153.4 | +4.9% | +39.7% | 44 |
| NVS Novartis AG | $307.0B | — | — | +18.2% | 36 |
| AZN AstraZeneca PLC | $289.1B | — | — | +106.8% | 0 |
| ABT Abbott Laboratories | $190.4B | 40.9 | +10.0% | −11.0% | 20 |
| NVO Novo-Nordisk A/S | $177.7B | — | — | −21.0% | 15 |
| VYNE VYNE Therapeutics Inc. Common Stock | $19M | — | −41.0% | −1.5% | — |
| Peer median | $334.4B | 45.8 | +10.0% | +29.3% | 28 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
183.97K
SI % of Float
0.58%
Days to Cover
1.00
Short Vol Ratio
42.6%
Free Float
31.60M
Float %
94.8%
Short interest 2026-07-15 • Short volume 2026-07-27 • Float 2026-02-17